Abstract
Therapeutic application of natalizumab, an anti-CD49d Ab, in patients with multiple sclerosis (MS) has been associated with increased levels of circulating CD34+ progenitors. We analyzed the frequency, phenotype and functional activity of CD34+ HSC in blood and BM of patients with MS who were treated with natalizumab. Compared with healthy controls and untreated MS patients, natalizumab treatment increased CD34+ cells in the peripheral blood 7-fold and in BM 10-fold. CD34+ cells derived from blood and marrow of natalizumab-treated patients expressed less of the stem cell marker CD133, were enriched for erythroid progenitors (CFU-E) and expressed lower levels of adhesion molecules than G-CSF-mobilized CD34+ cells. The level of surface CXCR-4 expression on CD34+ cells from patients treated with natalizumab was higher compared with that of CD34+ cells mobilized by G-CSF (median 43.9 vs 15.1%). This was associated with a more than doubled migration capacity toward a chemokine stimulus. Furthermore, CD34+ cells mobilized by natalizumab contained more mRNA for p21 and less for matrix metallopeptidase 9 compared with G-CSF-mobilized hematopoietic stem cell (HSC). Our data indicate that G-CSF and CD49d blockade mobilize different HSC subsets and suggest that both strategies may be differentially applied in specific cell therapy approaches.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Copelan EA . Hematopoietic stem-cell transplantation. New Engl J Med 2006; 354: 1813–1826.
Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–644.
Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666–1672.
Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275–282.
Roberts AW, DeLuca E, Begley CG, Basser R, Grigg AP, Metcalf D . Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995; 13: 512–516.
Moncada V, Bolan C, Yau YY, Leitman SF . Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003; 43: 495–501.
Dipersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.
Papayannopoulou T, Nakamoto B . Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 1993; 90: 9374–9378.
Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T . Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997; 90: 4779–4788.
Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361: 1075–1080.
Linda H, von HA, Major EO, Ryschkewitsch C, Berg J, Olsson T et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361: 1081–1087.
Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R . The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008; 111: 3893–3895.
Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T . Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111: 3439–3441.
Vuaillat C, Androdias G, Davoust N, Nataf S . About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors. Blood 2008; 112: 208–209.
Forsberg EC, Smith-Berdan S . Parsing the niche code: the molecular mechanisms governing hematopoietic stem cell adhesion and differentiation. Haematologica 2009; 94: 1477–1481.
Sugiyama T, Kohara H, Noda M, Nagasawa T . Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977–988.
Nie Y, Han YC, Zou YR . CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008; 205: 777–783.
Wilson A, Trumpp A . Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6: 93–106.
Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ . Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187–196.
Watanabe T, Dave B, Heimann DG, Lethaby E, Kessinger A, Talmadge JE . GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression. Bone Marrow Transplant 1997; 19: 1175–1181.
Christopher MJ, Liu F, Hilton MJ, Long F, Link DC . Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 2009; 114: 1331–1339.
Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montano J, Chang H et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood 1999; 93: 3379–3390.
Fukuda S, Bian H, King AG, Pelus LM . The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 2007; 110: 860–869.
Fargeas CA, Corbeil D, Huttner WB . AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells 2003; 21: 506–508.
Hess DA, Wirthlin L, Craft TP, Herrbrich PE, Hohm SA, Lahey R et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006; 107: 2162–2169.
Freund D, Oswald J, Feldmann S, Ehninger G, Corbeil D, Bornhauser M . Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor. Cell Prolif 2006; 39: 325–332.
Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009; 114: 1340–1343.
Acknowledgements
We thank Claudia Garten, Anja Zenkel, Anja Maiwald and Diana Döhler for the excellent technical assistance. Michelle Meredyth Stewart is acknowledged for critically reading the paper. This work was supported by the Deutsche Forschungsgemeinschaft (SFB655 to GE and MB) and the Centre for Regenerative Therapies Dresden (www.crt-dresden.de).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Jing, D., Oelschlaegel, U., Ordemann, R. et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 45, 1489–1496 (2010). https://doi.org/10.1038/bmt.2009.381
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.381
Keywords
This article is cited by
-
Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML)
Journal of Neuroimmune Pharmacology (2019)
-
Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis
BMC Medical Genomics (2018)
-
New agents in HSC mobilization
International Journal of Hematology (2017)
-
Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients
Journal of NeuroVirology (2016)
-
Cell Adhesion Molecules in Normal and Malignant Hematopoiesis: from Bench to Bedside
Current Stem Cell Reports (2016)